Transaction · 0001810417-26-000019

Sullivan Christopher Ryan

Sullivan Christopher Ryan, CFO, reported an open-market or private sale at Avalo Therapeutics, Inc. involving 37945.000000 shares for an estimated $753333.47. Reported holdings after the transaction were 43649.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCFO
AVTXAvalo Therapeutics, Inc.
Filing timeAug 19
Trade dateAug 17, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$20.75
Pre-filing
1mo ago -6.7%1w ago -4.7%1d ago -5.6%
Returns since
7d -1.0%30d -8.7%90d -8.7%180d -8.7%1y -8.7%

AVTX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
AVTX since 2026-08-19Filed 17 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001810417-26-000019
Common Stock
Transaction date
Aug 17, 2026
Filed Aug 19, 2026, 08:10 PM · 2d delay
Shares
37.9k sh
$1.98k per share
Estimated value
-$75.3M
Computed from shares × price
Holdings after
43.6k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership Large Holdings Reduction 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.

  2. F2

    The reported securities were sold in multiple transactions at prices ranging from $19.16 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the s…

  3. F3

    The reported securities were sold in multiple transactions at prices ranging from $19.70 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the s…

  4. F4

    The reported securities were sold in multiple transactions at prices ranging from $20.00 to $20.265. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the…

  5. F5

    The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.

Original filing · 0001810417-26-000019
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

AVTX